Custom cancer vaccine trial offers hope for Chemotherapy-Intolerant patients
NCT ID NCT06496373
Summary
This early-phase study is testing a personalized mRNA vaccine designed to target a patient's specific cancer, combined with an immunotherapy drug (PD-1 inhibitor). It is for people who have had surgery for pancreatic cancer but cannot tolerate standard chemotherapy. The main goal is to check the safety of this combination and see if it can help prevent the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.